Paul R. Solomon

Schizophrenia Research Foundation — India

Medicine · Health Sciences

44h-index12.5kcitations254works2.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Dementia and Cognitive Impairment Research(41), Neuroscience and Neuropharmacology Research(40), Memory and Neural Mechanisms(37), Alzheimer's disease research and treatments(20), Cholinesterase and Neurodegenerative Diseases(17)

Publications252 total

Barriers to seeking mental health services among young persons with mental disorders in South India: a qualitative study
East Asian Archives of Psychiatry·2025Open Access
1978 Donanemab in early symptomatic Alzheimer’s Disease: Efficacy and safety in TRAILBLAZER-ALZ 2, Phase 3 Randomized Clinical Trial
Age and Ageing·2024· 4 cited
Donanemab in Early Symptomatic Alzheimer’s Disease: Efficacy and Safety in TRAILBLAZER‐ALZ 2, a Phase 3 Randomized Clinical Trial
Alzheimer s & Dementia·2023· 13 citedOpen Access
Donanemab in Early Symptomatic Alzheimer Disease
JAMA·2023· 2.2k citedOpen Access
TRAILBLAZER-ALZ 2: A Phase 3 Study to Assess Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease (P18-3.005)
Neurology·2022· 7 cited
Combining Science and Humanities to Assess and Promote the Development of Visual‐Spatial Skills in Medical Learners
The FASEB Journal·2021
Intepirdine as adjunctive therapy to donepezil for mild‐to‐moderate Alzheimer's disease: A randomized, placebo‐controlled, phase 3 clinical trial (MINDSET)
Alzheimer s & Dementia Translational Research & Clinical Interventions·2021· 33 citedOpen Access
PO-1797: Dosimetric analysis of simultaneous integrated boost in the HYPORT Adjuvant Trial (NCT03788213)
Radiotherapy and Oncology·2020
ACCT1310-01.Accounting Principles I.Sp18.Solomon,Paul
Digital Commons - Hamline (Hamline University)·2018
The 10th International Medicinal Mushrooms Conference (September 19–22, 2019, Nantong, China)
International journal of medicinal mushrooms·2018Open Access
Response to Seán Manning’s Article: “Why Psychotherapy Must Be Secular”
Ata Journal of Psychotherapy Aotearoa New Zealand·2016Open Access
A randomized, double‐blind, placebo controlled, parallel group, efficacy study of alpha BRAIN® administered orally
Human Psychopharmacology Clinical and Experimental·2016· 9 cited
FIRST CIRCULAR OF THE 9TH INTERNATIONAL MEDICINAL MUSHROOMS CONFERENCE 24-28 September 2017, Palermo, Italy
International journal of medicinal mushrooms·2016Open Access
FIRST CIRCULAR OF THE 9TH INTERNATIONAL MEDICINAL MUSHROOMS CONFERENCE 24-28 September 2017, Palermo, Italy
International journal of medicinal mushrooms·2016Open Access
A clinical trial to validate event‐related potential markers of Alzheimer's disease in outpatient settings
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring·2015· 70 citedOpen Access
A randomized, double-blind, placebo controlled, parallel group, efficacy study of alpha BRAIN<sup>®</sup> administered orally
Journal of the International Society of Sports Nutrition·2015· 7 citedOpen Access
Non-pharmacological Treatment of Memory Loss, Alzheimer's Disease, and Dementia
Elsevier eBooks·2015· 1 cited
Special Issues in Memory Loss, Alzheimer's Disease, and Dementia
Elsevier eBooks·2015· 2 cited
Evaluating the Patient with Memory Loss or Dementia
Elsevier eBooks·2015· 12 cited
Alzheimer's Disease Dementia and Mild Cognitive Impairment Due to Alzheimer's Disease
Elsevier eBooks·2015· 6 cited
page 1 of 13Next →

Frequent Co-authors

William W. Pendlebury(5), Andrew E. Budson(5), Richard F. Thompson(4), Donald J. Weisz(3), Andrew Crider(3), Lawrence Kaplan(3), Judith L. Lewis(3), Joseph J. LoTurco(3), Ellen R. Vander Schaaf(2), John W. Moore(2), Anthony R. Turi(2), Felicity Adams(2), Richard D. DeVeaux(2), Donna M. Staton(2), G. Thomas Stowe(2), William W. Pendlbeury(2), Dean Pomerleau(2), Laurie Bennett(2), Julia M. James(2), et al(2)